# Semaglutide: An Independent Review of the Clinical Trial Record > Semaglutide produced mean 14.9% weight loss at 68 weeks in STEP 1 and a 20% MACE reduction in SELECT. An independent digest of what the trials actually measured. Fourteen thousand participants, multiple regulatory decisions, two decades of clinical evidence. A hard-wearing, plainspoken review of the semaglutide research record — strengths named, limitations stated, every quantitative claim cited. ## The Semaglutide evidence base: what it covers Semaglutide is a synthetic GLP-1 receptor agonist studied across more than twenty registered clinical trials spanning type 2 diabetes management, weight reduction in obesity, and cardiovascular risk reduction. The compound carries multiple FDA approvals and one of the largest Phase 3 clinical trial programs for any single peptide-derived compound in recent history. The core findings are reproducible: once-weekly subcutaneous semaglutide at 2.4 mg produced mean body-weight reduction of 14.9% at 68 weeks versus 2.4% with placebo in STEP 1 (N=1,961) [1]. Two-year data from STEP 5 sustained that effect at 15.2% mean reduction [2]. The SELECT trial (N=17,604) documented a 20% reduction in major adverse cardiovascular events in adults with obesity but without diabetes over 208 weeks [7]. Those are the headline numbers. The gaps matter too: weight regain after discontinuation averages 11.6 percentage points within one year [3]; absolute lean body mass decreases alongside fat mass [15]; GI adverse effects are dose-dependent and present in the majority of trial participants during escalation phases [13]. This site documents both. For [semaglutide dosing protocols](/dosage), [semaglutide side effects](/side-effects), and [semaglutide for weight loss](/weight-loss), dedicated pages cover the respective literature in depth. ## Semaglutide as a GLP-1 Receptor Agonist Semaglutide shares 94% sequence homology with native GLP-1, modified with two structural changes that extend its half-life from approximately 2 minutes (native GLP-1) to approximately 145-168 hours [10]. The Aib8 substitution confers resistance to dipeptidyl peptidase-4 (DPP-4) cleavage; the C18 fatty diacid chain at Lys26, via a glutamate linker, enables reversible albumin binding that slows renal clearance [12]. The result: once-weekly subcutaneous dosing in clinical studies. Native GLP-1 could not sustain the physiological effect across that interval; semaglutide's structural modifications are specifically engineered to do so. GLP-1 receptors are expressed in pancreatic beta cells, hypothalamic appetite circuits, the brainstem (area postrema and nucleus tractus solitarius), and the gastrointestinal tract. Semaglutide activates all of these. The multi-site activation is what produces the compound's overlapping glycemic, weight, and cardiovascular effects documented across the STEP, SUSTAIN, and SELECT programs. ## What is Semaglutide? A 31-amino acid synthetic analogue of human GLP-1, molecular weight 4113.6 Da. Available in two formulations studied clinically: once-weekly subcutaneous injection and once-daily oral tablet. The structural modifications are the point — semaglutide is not simply a GLP-1 analogue but a specifically engineered half-life extension of it [12]. FDA approval history: subcutaneous injection for type 2 diabetes (2017), oral tablet for type 2 diabetes (2019), subcutaneous injection for chronic weight management (2021), and a cardiovascular risk reduction label expansion following the SELECT trial results (2024). Compounded formulations produced outside the FDA-approved manufacturing chain are not approved and have been the subject of FDA safety warnings regarding dosing errors and product quality concerns. ## Is Semaglutide a GLP-1 receptor agonist? Yes. Semaglutide is a synthetic analogue of human GLP-1 with 94% sequence homology, modified with a C18 fatty diacid chain and two amino acid substitutions (Aib8, Arg34) that extend half-life from approximately 2 minutes (native GLP-1) to approximately 168 hours [12]. The extended half-life enables once-weekly subcutaneous dosing or once-daily oral dosing in clinical protocols. ## Trial record: scope and coverage The semaglutide clinical program is one of the largest for any GLP-1 receptor agonist. STEP 1-5, STEP TEENS — weight management. SUSTAIN 1-6 — type 2 diabetes glycemic control and cardiovascular safety. PIONEER 1-8 — oral formulation (type 2 diabetes). SELECT — cardiovascular outcomes in obesity without diabetes. Across these programs: tens of thousands of participants, multiple years of follow-up, multiple pre-specified secondary endpoints covering cardiometabolic biomarkers, body composition, and quality of life. This site covers the published findings from that record — mechanism, efficacy, safety profile, pharmacokinetics, and the open questions the trials have not yet answered. See the [semaglutide mechanism of action](/research#mechanism) section on the research page, [cardiovascular outcomes research](/research#cardiovascular) for SELECT and SUSTAIN-6 data, and [frequently asked questions](/faq) for direct answers to the most-searched questions about the compound. --- A trial-by-trial weighing of the semaglutide evidence record — STEP, SUSTAIN, SELECT, PIONEER — reported plainly, cited fully, and sold by no one.